Last reviewed · How we verify
A-101 Solution 45
A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation.
A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation. Used for Seborrheic keratosis, Actinic keratosis.
At a glance
| Generic name | A-101 Solution 45 |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | Topical keratolytic agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
A-101 is a proprietary formulation containing high-concentration hydrogen peroxide and other active ingredients designed for direct application to skin lesions. It works by inducing controlled chemical destruction of the target tissue, leading to lesion removal. The solution is applied topically in a controlled manner to minimize damage to surrounding healthy skin.
Approved indications
- Seborrheic keratosis
- Actinic keratosis
Common side effects
- Application site irritation
- Application site erythema
- Application site pain or burning
- Hyperpigmentation
- Hypopigmentation
Key clinical trials
- Safety Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- A Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- A Study of A-101 Solution in Subjects With Common Warts. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A-101 Solution 45 CI brief — competitive landscape report
- A-101 Solution 45 updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI